Ocular toxicity of mitogen-activated protein kinase inhibitors
Menée au Royaume-Uni à partir de données portant sur 40 patients atteints de cancer et inclus dans des essais cliniques sur la période 2011-2013, cette étude analyse la toxicité oculaire de trois types d'inhibiteurs de MEK
The Oxford Eye Hospital and the Oxford Experimental Cancer Centre collaborate in monitoring patients in a number of early-phase clinical trials. In this study, we report the ocular toxic effects of 3 different mitogen-activated protein kinase inhibitors (MEKIs) currently at independent stages of clinical development, including ongoing studies. Forty clinical records of patients enrolled in clinical trials of 3 different MEKIs (including 11, 19, and 10 patients in MEKI trials A, B, and C, respectively) were reviewed from March 16, 2011, to April 25, 2013. Baseline visual acuity and ophthalmic imaging data, including macular optical coherence tomography, relevant ophthalmic and general medical history, evidence of ocular toxic effects in addition to the clinical course, and relevant interventions, were recorded and analyzed